To date, no conventional meta-analysis or network meta-analysis (NMA) has systematically quantified the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors while accounting for dose. The gene discussed is GLP1R; the disease is intestinal obstruction.